Peter Valent. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities. Haematologica 2011;96(10):1395-1397; https://doi.org/10.3324/haematol.2011.052076.